| Name | Title | Contact Details |
|---|
In 1990, Nitro Snowboards was founded by Thomas Delago and Sepp Ardelt in Seattle, Washington. Over the last 25 years Nitro has helped grow the sport of snowboarding through its groundbreaking product development, marketing, movies, grass roots events, and global team of world class snowboarders. Today Nitro has grown its product to offer all the essentials needed for having a good time snowboarding and traveling. Nitro´s headquarters are divided all over the world from the Mountains of Oberammergau, to the worlds best snow in Salt Lake City, UT, to the creative beaches of California, all the way up to the Northwest snowboarding destination of Vancouver, British Colombia. For more information visit us at http://www.nitrosnowboards.com or @NITROUSA on Instagram
Inspired by high performance experiences, AllTeam Sportswear was founded to offer premium sportswear and equipment that equip athletes to perform at the highest level. From elite athletes to those just starting out, AllTeam Sportswear is the thread that unites us.
Atomic Provisions is a restaurant group that exists to nourish our staff, guests and community with simple-perfected food and service...one slice, one biscuit, one ice cream and one beer at a time. We are growing...and with us you can grow too!
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.